Vertex Ventures SEA

Vertex Ventures Southeast Asia and India is one of the region’s leading early-stage funds with deep operator credentials, multiple fund vintages, and a confirmed digital health track record including Speedoc, the Singapore-based virtual hospital platform that the firm led at Series A and continued to support through pre-Series B. Stage focus spans seed through Series B with checks in the $1M to $25M range. The firm operates as part of the broader Vertex Holdings platform, which is wholly owned by Singapore’s Temasek, giving it institutional weight and follow-on capacity that few regional funds match. AI is not flagged as a primary focus, but the fund’s portfolio is increasingly AI-touched in practice. The right founder for Vertex SEA is a Southeast Asian or Indian healthcare technology operator at seed or Series A, ideally with credible commercial traction, building digital health, healthcare software, or tech-enabled care delivery with strong unit economics and regional ambition. The wrong founder is a deep medtech hardware team, a consumer wellness brand without B2B traction, or a US-pedigreed founder without local market thesis. Intro paths run through Singapore’s tight venture community, frequent co-investors and follow-on partners including EDBI, Wavemaker Partners, Openspace Ventures, Insignia, Heritas Capital, and the broader Temasek family of funds, and through Vertex’s existing portfolio CEOs many of whom are publicly active. Direct outreach is read by the team but warm intros materially help in a competitive deal market. In the pitch, lead with cohort retention, real revenue, and a credible regional expansion story across at least two or three Southeast Asian or Indian markets, and a candid view of the public-private payer dynamics in each market. Be specific about MOH Singapore, BPOM Indonesia, FDA Thailand, FDA Philippines, MOH Vietnam, and CDSCO India regulatory posture as relevant. Show that you understand the differences between Speedoc-style virtual hospital models and other digital health archetypes, and where your business sits in that taxonomy. Caveats include the increased competitiveness of Southeast Asian Series A in 2024-2025 which has compressed timelines, the reality that Vertex’s broader mandate spans many sectors which means partner attention is selective, and the typical institutional diligence depth that requires founders to come prepared with audit-ready data rooms. For credible Southeast Asian or Indian healthcare technology founders, Vertex is a top-tier regional partner with strong follow-on capacity.